1. Technology Overview
Congenital adrenal hyperplasia (CAH) is an inherited disorder frequently found in paediatrics caused by the deficiency of enzyme 21-hydroxylase where the level of the steroid 17æ hydroxyprogesterone (17OHP) in the body is increased. The determination of 17OHP is clinically useful for the diagnosis and management of CAH. Six mouse hybridoma cell lines that produce and secrete monoclonal antibodies (Mabs) specifically bind to 170HP were generated. these Mabs were incorporated in a competitive enzyme immunoassay (EIA) for the measurement of 17OHP in blood and other tissues. these Mabs competes with the antibodies from the patient’s serum for binding to the immobilized 17OHP. the bound mouse Mabs was detected by a secondary sheep anti-mouse immunoglobulin (IgG) conjugated to horseradish peroxidase and a chromogenic substrate ABTS. The colour development was determined by ELISA plate reader at 405 nm. This system can be developed into kits for rapid and sensitive detection and quantification of 17OHP.
- UMCIC File Number: 628/38
- Patent: MY-157979-A
- Patent status: Granted
- Malaysia patent: Monoclonal Antibodies From Hybridoma Cell Lines For Detecting 17Alpha-Hydroxyprogesterone In Cogenital Adrenal Hyperplasia
- This technology is currently available for licensing and commercialisation.